Shiratori M, Saitou K, Inukai A, Aoki S, Sobue G
Department of Neurology, Nagoya University, School of Medicine, Japan.
Rinsho Shinkeigaku. 1996 Jun;36(6):793-6.
High-dose intravenous immunoglobulin therapy for multifocal motor neuropathy (MMN) exhibits a beneficial, but temporary effect in most cases. We experienced a patient with MMN having a high titer of anti-GM1 ganglioside antibody. He was weekly administered human immunoglobulin, and his muscle strength was successfully improved and maintained at the improved level after high-dose human immunoglobulin infusion. The pattern of improvement and maintenance by weekly administration of human immunoglobulin was variable among the muscles; e.g. only a minimal improvement was observed in the most severely involved brachioradial muscles. Successive measurements with a hand-held dynamometer revealed in detail the changes in the strength of each muscle during treatment. Anti-GM1 ganglioside antibody titers did not significantly change during the treatment, but a slight improvement in motor conduction amplitudes and velocities was observed in mildly affected nerves. Our findings suggest that weekly administration of human immunoglobulin is a safe and effective therapy for MMN and that the anti-GM1 ganglioside antibody titer may not be a good indicator for this therapy.
大剂量静脉注射免疫球蛋白治疗多灶性运动神经病(MMN)在大多数情况下显示出有益但短暂的效果。我们遇到一名患有高滴度抗GM1神经节苷脂抗体的MMN患者。他每周接受人免疫球蛋白治疗,在大剂量输注人免疫球蛋白后,其肌肉力量成功改善并维持在改善后的水平。每周注射人免疫球蛋白后肌肉改善和维持的模式在不同肌肉间存在差异;例如,在受累最严重的肱桡肌中仅观察到极小的改善。使用手持测力计进行的连续测量详细揭示了治疗期间每块肌肉力量的变化。治疗期间抗GM1神经节苷脂抗体滴度没有显著变化,但在轻度受累神经中观察到运动传导幅度和速度略有改善。我们的研究结果表明,每周注射人免疫球蛋白是治疗MMN的一种安全有效的方法,并且抗GM1神经节苷脂抗体滴度可能不是该治疗的良好指标。